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ABSTRACT 
Background and Aims: People who have recently injected drugs are a priority population in 
efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence 
and number of people with recent injecting drug use living with HCV, and the proportion of 
people with recent injecting drug use among all people living with HCV infection at global, 
regional, and country-levels. 
Methods: Data from a global systematic review of injecting drug use and HCV antibody 
prevalence among people with recent (previous year) injecting drug use were used to estimate 
the prevalence and number of people with recent injecting drug use living with HCV. These 
data were combined with a systematic review of global HCV prevalence to estimate the 
proportion of people with recent injecting drug use among all people living with HCV. 
Results: There are an estimated 6.1 million [95% uncertainty interval (UI) 3.4-9.2] people 
with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic 
prevalence; UI 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, 
UI 1.0-2.1), Eastern Europe (1.5 million, UI 0.7-2.4), and North America (1.0 million, UI 
0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI 4.6-13.1) of 
all HCV infections globally, with the greatest proportions in North America (30.5%, UI 11.7-
56.7), Latin America (22.0%, UI 15.3-30.4), and Eastern Europe (17.9%, UI 8.2-30.9).  
Conclusions: Although about forty-percent of people with recent injecting drug use are 
living with HCV and almost nine percent of all HCV infections globally occur among people 
with recent injecting drug use, there is wide variation globally.   
Funding: National Drug and Alcohol Research Centre, UNSW Sydney; Australian National 
Health and Medical Research Council; John C Martin Foundation. 
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INTRODUCTION 
The World Health Organization (WHO) has set a goal to eliminate hepatitis C virus (HCV) as 
a global public health threat by 2030 (1). Between 2015 and 2030, WHO targets include 
reducing new HCV infections by 80%, the number of HCV deaths by 65%, and increasing 
HCV diagnoses from 20% to 90% and eligible persons receiving HCV treatment from <5% 
to 80%. People who inject drugs represent a priority population for HCV elimination, given 
the high prevalence and incidence in this group (2-7).  
 
We previously estimated the global, regional, and country-level prevalence of HCV (viraemic  
infections) (8). In 2015, the global prevalence of HCV infection was estimated to be 1.0% 
(95% uncertainty interval 0.8–1.1), corresponding to 71.1 million (62.5–79.4) people living 
with HCV (8). We also estimated the global, regional, and country-level HCV antibody 
prevalence among people with recent injecting drug use (previous 12 months). Among the 
estimated 15.6 million [uncertainty intervals (UI) 10.2-23.7 million] people with recent 
injecting drug use aged 15-64 years globally, it is estimated that 52.3% (UI 42.4-62.1%) are 
HCV-antibody positive, representing 8.2 million people who have recently injected drugs (UI 
4.7-12.4 million) with past or present HCV (7). Given that 25% of people spontaneously 
clear HCV infection (9), estimates are needed on the prevalence and numbers of people with 
recent injecting drug use who are living with HCV infection (viraemic infection).   
 
There are no previous estimates at the global, regional, and country-levels of the HCV RNA 
(Ribonucleic acid) prevalence among people with recent injecting drug use, the number of 
people with recent injecting drug use who are living with HCV infection (HCV RNA 
detectable or viraemic), or the proportion of people with recent injecting drug use among all 
people living with HCV infection. These data are crucial to monitor progress of global HCV 
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elimination efforts and identify high-burden settings to enable appropriate targeting of 
prevention and treatment strategies to achieve the WHO HCV targets. 
 
The aim of this study was to estimate the global HCV RNA prevalence (viraemic infections) 
among people who have recently injected drugs; the numbers of people with recent injecting 
drug use living with HCV infection; and the proportion of people who have recently injected 
drugs among all people living with HCV at global, regional, and country-levels.  
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Methods 
Study design and procedures 
This analysis utilized data from two published studies. The first study was a systematic 
review to estimate the number of people with recent injecting drug use and the HCV antibody 
(anti-HCV) prevalence among people who have recently (previous 12 months) injected drugs 
(10). The second study was a systematic review and modelling study to estimate the global 
viraemic HCV prevalence (8).  
 
The first systematic review estimated global, regional, and country-level prevalence of 
injecting drug use among people aged 15–64 years; and the prevalence of HIV, HCV, and 
hepatitis B virus (HBV) among people with recent injecting drug use in 2015 (7). This review 
was performed consistent with the GATHER and PRISMA guidelines. Multiple search 
strategies (7) were used to identify papers and reports published since previous reviews of 
IDU prevalence (from 2008) (11) and of HCV amongst PWID (from 2011) (12). Without 
language restrictions, peer-reviewed databases (MEDLINE, Embase, and PsycINFO), and 
grey literature were systematically searched, and data requests disseminated to international 
experts and agencies. We searched for data on IDU prevalence, and the prevalence of HIV, 
HCV, and HBV among people with recent injecting drug use. Eligible data on prevalence of 
IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where 
multiple estimates were available, pooled for each country via random effects meta-analysis. 
Data on HCV RNA prevalence among people with recent injecting drug use were also 
extracted. Global, regional, and country-level estimates of the HCV antibody (anti-HCV) 
prevalence among people with recent injecting drug use were used for the current study (7).  
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The second systematic review estimated global, regional, and country-levels viraemic HCV 
prevalence in 2015 (8). Data published between January 1, 2000 and March 31, 2016 were 
identified through searches of electronic peer-reviewed literature databases, PubMed and 
Embase (8). Non-indexed government reports, personal communication with country experts, 
and additional studies identified through manual searches of references noted in publications 
were included where better data were not available. Articles were scored on the degree to 
which they could be extrapolated to the general population, the sample size, and the year of 
analysis. A Microsoft Excel-based (version 2007) Markov-type model was populated with the 
highest-scoring epidemiological data for each country, used to estimate HCV prevalence over 
time (including in 2015). A Delphi process was used to gain country expert consensus and 
validate inputs. Further details of data extraction, scoring of data sources, Delphi process, and 
modelling, have been published (8). Global, regional, and country-level estimates of the 
numbers of people with viraemic HCV infection were used for the current study (7). 
 
Statistical Analysis 
First, we sought to estimate the prevalence of viraemic HCV infection (detectable HCV 
RNA) among people with recent injecting drug use at global, regional, and country-levels. As 
shown in Table 1, 48% (98 of 206) of countries had available data on HCV antibody 
prevalence among people with recent injecting drug use (n=374 studies) as compared to only 
9% (19 of 206) of countries with available data on HCV RNA prevalence among people with 
recent injecting drug use (n=32 studies). Compared to studies of HCV antibody prevalence 
among people with recent injecting drug use (n=374), studies of HCV RNA prevalence 
among people with recent injecting (n=32), were less often estimate grade A (multi-site 
seroprevalence study with >1 sample types) (6.3% vs. 21.9%) and national samples (20.6% 
vs. 6.2%). Given the poor availability of data on HCV RNA prevalence, we sought to 
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estimate the HCV viraemic proportion (those living with HCV infection) by using estimates 
of the prevalence of HCV antibodies among people with recent injecting drug use within each 
country (7) and multiplying by an estimate of the proportion developing viraemic HCV 
infection (9). The proportion with viraemic HCV infection among those who were HCV 
antibody positive [75%; 95% confidence interval (CI) 71%, 79%] was estimated using data 
from a well-characterized merged dataset of nine international cohorts of people who had 
recently injected drugs who had acquired acute HCV infection and were followed 
prospectively for spontaneous HCV clearance and viraemic infection (9). The number of 
people with recent injecting drug use with viraemic HCV infection was then estimated by 
multiplying the number of people with recent injecting drug use by the HCV viraemic 
prevalence.  
 
95% uncertainty intervals (UI) were estimated using Monte Carlo simulation taking 100,000 
draws. A binomial distribution was used because the parameters of interest were proportions 
(product of IDU proportion among population and HCV proportion among PWID). Estimated 
sample sizes were derived based on the 95% CIs and standard errors of proportion estimates 
in each country. The simulated UIs incorporated the uncertainty of estimates.  
 
Following the collation of country-specific estimates, estimates of regional and global 
viraemic HCV infection among people with recent injecting drug use were derived. Region-
specific, weighted estimates of the prevalence of HCV were made using all the observed 
estimates and 95% CI of estimates in each country within that region and deriving a weighted 
estimate and UI taking into account country population size. Regional estimates were then 
used to estimate the global prevalence.  
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The proportion of people with recent injecting drug use among all people living with HCV 
infection was computed by dividing the total number of people with recent injecting drug use 
living with HCV by the total number of all people living with HCV for countries where both 
estimates were available. As above, 95% UIs were simulated taking 100,000 draws carrying 
forward the standard errors for both people with recent injecting drug use living with HCV 
and the total HCV viraemic infection prevalence estimates. 
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RESULTS 
Sufficient data were identified to enable estimates of the HCV viraemic prevalence among 
people with recent injecting drug use in 98 countries, and to estimate the population size of 
people with recent injecting drug use living with HCV in 76 countries. Sufficient data were 
identified to enable estimates of the number of people living with HCV overall in 98 
countries. There were sufficient data to estimate the number of people with recent injecting 
drug use as a proportion of all people living with HCV in 55 countries. 
 
Results are shown by region in Table 2 and by country in Table 3. Globally, we estimate that 
in 2015, 39.2% (UI 31.6-47.0) of people with recent injecting drug use have HCV viraemic 
infection, representing 6.1 million (UI 3.4-9.2) people with recent injecting drug use living 
with HCV infection globally. Of the 71.1 million (UI 62.5-79.4 million) people living with 
HCV infection (Table 2), we estimate that 8.5% (UI 4.6-13.1) are people with recent injecting 
drug use (Table 2). 
 
At the regional level, HCV viraemic prevalence among people with recent injecting drug use 
varied from 16.3% (UI 12.7-20.1) in Sub-Saharan Africa to 48.6% (UI 42.0-55.2) in Eastern 
Europe (Table 2). The largest estimated numbers of people with recent injecting drug use 
living with HCV infection were in East and Southeast Asia (1.5 million, UI 1.0-2.1), Eastern 
Europe (1.5 million, UI 0.7-2.4), and North America (1.0 million, UI 0.4-1.7). The proportion 
of people with recent injecting drug use among all people living with HCV infection ranged 
from 1.5% (UI 0.7-2.4) in the Middle East and North Africa to 30.5% (UI 11.7-56.7) in North 
America (Table 2). Regions with people with recent injecting drug use comprising >10% of 
all people living with HCV infection included Latin America (22.0%, UI 15.3-30.4), Eastern 
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Europe (17.9%, UI 8.2-30.9), Australasia (17.7%, UI 12.1-25.2), Caribbean (16.7%, 8.9-
30.6), and Western Europe (17.2%, UI 9.9-30.4).  
 
At the country-level, there was very marked variation in the estimates of HCV viraemic 
prevalence between countries, ranging from 0.5% (UI 0.0-1.4; Maldives) to 72.8% (UI 68.8-
76.7; Mauritius) [Figure 1 and Table 3]. The HCV viraemic prevalence was 60–80% in 10 
countries, 40-<60% in 38 countries, and <40% in 50 countries. The largest populations of 
people with recent injecting drug use living with HCV infection were in Russia (969,500; UI 
463,000-1,570,500), the United States (895,000; UI 353,500-1,601,500), China (828,000; UI 
493,000, 1,228,500), and Brazil (461,000, UI 336,500-596,500) [Figure 2 and Table 3]; 
together, these countries accounted for 51% of people with recent injecting drug use living 
with HCV infection. The top 25 countries accounting for 82% of all people with recent 
injecting drug use living with HCV infection globally are shown in Figure 3.  The proportion 
of people with recent injecting drug use among all people living with HCV infection varied 
between 0.9% (UI 0.4-3.0; India) and 46.6% (UI 22.1-100.0; Commonwealth of Puerto Rico) 
[Figure 4 and Table 3]. The proportion of people with recent injecting drug use among all 
people living with HCV infection was <10% in 21 countries, >10-<20% in 11 countries, and 
>20% in 23 countries.   
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DISCUSSION 
This study estimated that there are 6.1 million (UI 3.4-9.2) people with recent injecting drug 
use living with HCV infection worldwide, comprising 8.5% (UI 4.6-13.1) of all HCV 
infections globally. There was considerable variation in the prevalence of HCV infection 
among people with recent injecting drug use at regional and country-levels, and in the 
proportion of all HCV infection that is among people with recent injecting drug use. These 
findings highlight countries and regions where a focus on HCV prevention and treatment 
among people with recent injecting drug use will be required, if HCV elimination targets are 
to be met.  
 
The greatest numbers of people with recent injecting drug use living with HCV infection are 
in Eastern Europe, East and Southeast Asia, and North America. Half of all people with 
recent injecting drug use living with HCV infection are from just four countries: the Russian 
Federation, the United States, China, and Brazil. Further, the top 25 countries account for 
82% of all people with recent injecting drug use living with HCV infection globally. 
Although PWID are a critical population for HCV elimination in many settings, concerted 
efforts to increase access to prevention and treatment for people with recent injecting drug 
use in these countries will be pivotal to the success of global HCV elimination efforts. Key 
among these will be harm reduction measures to prevent incident infections (13), and 
increased testing, linkage to care and uptake of directly-acting antiviral therapy among people 
with recent injecting drug use (14, 15). 
 
Countries or territories where it is estimated that at least one-third of people living with HCV 
infection are people with recent injecting drug use include Georgia, Austria, Finland, 
Malaysia, and Puerto Rico. In a further 16 countries, at least one-quarter of people living with 
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HCV infection are people with recent injecting drug use. However, there are also 21 countries 
where the proportion of people living with HCV are people with recent injecting drug use is 
<10%. Collectively, these data highlight the variation in the proportion of overall viraemic 
HCV infection occurring among people with recent injecting drug use globally, reflecting the 
differing epidemiology of HCV in different settings. As such, different types of prevention, 
testing, and treatment strategies will be needed to address HCV elimination targets according 
to the epidemiology within a given country. It should also be noted that there were 124 
countries and territories where injecting drug use is known to occur, but no data were 
available to assess the proportion of people with HCV infection who are people with recent 
injecting drug use.  
 
This study was limited to estimates among people with recent injecting drug use and will not 
include those who have even ‘temporarily’ or permanently ceased injecting. As such, this 
study underestimates the proportion of infections that occur among people who inject drugs 
within an overall epidemic, given that some infections due to injecting drug use will be 
among people with a history of injecting who have ceased injecting. It is critical to consider 
people who have recently injected drugs as well as those who have ceased injecting in the 
design of strategies to address HCV. 
 
There are several limitations to this study. The search may have missed some literature 
(particularly grey literature), despite our wide scope of online searchers and requests for 
information from people across many countries. To address this possibility, we liaised with 
the WHO, Global Fund, UNODC and UNAIDS staff to contact experts within countries and 
obtain reports that were not available online. However, we doubt that any missed papers will 
alter these findings in a meaningful fashion. 
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Errors may have been made in data extraction and interpretation. To reduce such errors, all 
sources and data from which the final estimates were derived were double-checked by at least 
two reviewers prior to inclusion with a further round prior to finalisation with a third 
reviewer. We have online interactive presentations of these data at [URL to be provided] to 
ensure full transparency and to increase the potential for people to interact with the estimates 
and results, and suggest additional data sources. We encourage feedback at 
global.reviews@unsw.edu.au.  
 
Although the review team searched for publications in multiple languages, we may have 
missed documents in languages in which we are not fluent. Those with access to data or 
papers/reports in other languages should contact us. It is also important to acknowledge a 
number of features of our approach to synthesis and imputation of estimates, driven by the 
gaps in data available. Although there has been a clear increase in efforts to quantify the 
extent of IDU and HCV among PWID, there are still major gaps in data in some regions. A 
hierarchical grading system was used to evaluate estimates based on geographical 
generalisability (e.g., from multiple sites) and across various populations of PWID (e.g., 
treatment and non-treatment samples). Exclusion of estimates based on a study’s 
methodology grade was only applied to estimates of IDU and anti-HCV prevalence. 
Nonetheless, our recent approach, which involved pooling estimates, and our more 
sophisticated approach to estimating uncertainty around all our estimates, including our 
method of estimating uncertainty around imputed estimates, are both improvements upon 
previous reviews. 
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A limitation is the lack of country-level data to estimate the viraemic HCV prevalence (98 
countries), numbers of people living with HCV (76 countries) and the proportion among the 
overall population living with HCV among people with recent injecting drug use (55 
countries). Data were sparse in regions such as the Caribbean, Latin America, Pacific Island 
States & Territories, Sub Saharan Africa, and the Middle East and North Africa. The 
estimates for these regions should be interpreted with caution and highlights that further work 
is needed to improve estimates in countries from these regions. 
 
In this study, data on HCV antibody prevalence [multiplied by an estimate of the proportion 
of people with HCV antibodies who would have active viraemia, 0.75 (95% CI, 0.71, 0.79)] 
was used to estimate the viraemic HCV prevalence, instead of actual data on HCV RNA 
prevalence. We opted for this approach because the data on HCV antibody prevalence was of 
higher quality and coverage, and there were few countries for which any data were available 
for HCV RNA (Table 1). Instead, we used data on the estimated viraemic prevalence from a 
well-defined series of nine prospective cohorts of acute HCV infection among people who 
inject drugs with well-characterized events of spontaneous clearance (9). Although this 
provides a very accurate estimate of the proportion who progress to viraemic infection, the 
limitation is that this approach may have either over-estimated or under-estimated the true 
prevalence of viraemic infection in people with recent injecting drug use in various settings. 
In some regions, increased reinfection risk and/or higher HIV prevalence may result in a 
higher viraemic prevalence and our approach may have underestimated the viraemic 
prevalence (16). Conversely, it is known that some factors (e.g. female sex) increase 
spontaneous clearance and can reduce the viraemic prevalence, which might have 
overestimated the viraemic prevalence observed. Also, these analyses did not take into 
consideration clearance due to HCV treatment, which might have led to an overestimation of 
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the prevalence and numbers of people with recent injecting drug use living with HCV 
infection. However, this is also unlikely to have affected these estimates as uptake of HCV 
treatment among PWID was very low prior to 2015 (17-21). This study clearly demonstrates 
the need to integrate HCV RNA testing into future studies of HCV among people with recent 
injecting drug use to enable the evaluation of viraemic HCV RNA prevalence to improve 
national, regional and global estimates, particularly given that larger numbers of PWID are 
initiating HCV treatment (and will be anti-HCV positive, but HCV RNA negative).  
 
Denominator data are also subject to limitations. General population data may be in error for 
some countries where accurate census data are lacking. Population sizes of people with recent 
injecting drug use were based on the best available empirical estimates for each country, but 
there is often considerable uncertainty around estimates of this population, which translates to 
uncertainty in estimates of the number of PWID with HCV infection and the proportion of 
HCV infections occurring among people with recent injecting drug use. Estimates of HCV 
viraemia in people with recent injecting drug use incorporated the uncertainties in the IDU 
population size, anti-HCV prevalence estimate, and viraemia multiplier. However, estimates 
of the prevalence of recent IDU and of HCV prevalence both in people with recent injecting 
drug use and in the general population are subject to biases, which may be responsible for 
some estimates that do not seem correct. Further, the extracted data was often from a single 
year and changes in injecting drug user populations and HCV incidence could not be 
measured. This highlights the importance of continuing to improve country-level estimates of 
people with recent injecting drug use and those with viraemic HCV infection.  
 
Irrespective of these limitations, this review advances our understanding of HCV prevalence 
and disease burden among people with recent injecting drug use. Accurate estimates of the 
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prevalence and burden of viraemic HCV infection among people with recent injecting drug 
use are crucial to guide policy and practice and guide the development of strategies to 
enhance testing, linkage to care and treatment in this population. This review highlights that 
concerted efforts will be required in countries with large numbers of people infected with 
HCV to achieve global HCV elimination among PWID. Further, it highlights that strategies 
to achieve a reduction in HCV burden will need to be tailored to the individual country, based 
on the HCV epidemiology and the proportion of overall infections occurring in people with 
recent injecting drug use. Collectively, these data will inform mathematical modelling to 
identify strategies to increase diagnosis, treatment and reduce the number of new infections to 
achieve HCV elimination at a country level. Further work is needed to better understand the 
population size of people with a history of injecting drug use and the prevalence of viraemic 
HCV infection and burden in those with former, but not recent, injecting drug use.  
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Table 1: Quality of evidence of countries with available HCV antibody prevalence and 
HCV RNA prevalence data among recent PWID 
 
HCV antibody prevalence 
among recent PWID 
(n=374) 
HCV RNA prevalence 
among recent PWID  
(n=32)  
Countries with available data 98/206 (47.6%) 19/206 (9.2%) 
Estimate grade*   
    A                           82 (21.9%) 2 (6.3%) 
    B1                  225 (60.2%) 20 (62.5%) 
    B2   13 (3.6%) 1 (3.1%) 
    C 54 (14.4%) 8 (25.0%) 
    U - 1 (3.1%) 
Geographic coverage   
    National sample                      77 (20.6%) 2 (6.2%) 
    Sub-national sample  87 (23.3%) 11 (34.4%) 
    City sample 210 (56.1%) 19 (59.4%) 
Literature type#   
    A1 128 (34.2%) 30 (93.75%) 
    A2               4 (1.1%) - 
    B2   147 (39.3%) - 
    B3 81 (21.7%) - 
    C   8 (2.2%) 2 (6.25%) 
    D 6 (1.6%) - 
*Grading for estimate grade: A - Multi-site seroprevalence study with >1 sample types (e.g. needle-syringe programmes, 
drug treatment centres, incarcerated IDUs), B1 - Seroprevalence study, single sample type and multiple sites; B2 - 
Seroprevalence study, multiple sample types and a single site; C - Seroprevalence study, single sample type; D - Registration 
or notification of cases of hepatitis/HIV infection; E - Prevalence study using self-reported hepatitis/HIV status; Ungraded - 
Estimate with methodology unknown. #Grading for literature type: A1 - Peer-reviewed journal article; A2 - Abstract of 
published article only; B1 - Published book/report/monograph from scholarly or commercial publisher;B2 - Published 
book/report/monograph from international governmental or monitoring organisation (e.g. UN, WHO, EMCDDA); B3 - 
Published book/report/monograph from other source (e.g. Government, NGO, university, research centre); C - Conference 
abstract; D - Other unpublished report (incl. Website downloads); E  - Email and private correspondence; F – ARQ.  
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Table 2: Regional and global estimates of the prevalence of HCV viraemic infection 
among people with recent injecting drug use, the number of people with recent injecting 
drug use living with HCV viraemic infection, the total population living with HCV 
vireamic infection and the proportion of people with recent injecting drug use among 
the total population with HCV viraemic infection 
 
 
Prevalence of 
HCV viraemic 
infection among 
people with recent 
injecting drug use 
% (UI) 
Number of people with recent 
injecting drug use living with 
HCV viraemic infection 
(UI) 
 
 
Total population living with HCV 
viraemic infection  
(UI) 
Proportion of 
people with 
recent injecting 
drug use among 
the total 
population with 
HCV viraemic 
infection 
% (UI) 
Eastern Europe 48.6 (42.0, 55.2) 1,466,500 (699,500, 2,377,000) 8,181,000 (6,304,000, 8,250,000) 17.9 (8.2, 30.9) 
Western Europe 39.9 (35.7, 44.1) 402,500 (264,500, 557,000) 2,347,000 (1,969,000, 3,289,000) 17.2 (9.9, 30.4) 
East and Southeast Asia 37.7 (28.2, 47.5) 1,506,000 (1,019,500, 2,078,500) 16,313,000 (12,636,000, 17,242,000) 9.2 (5.8, 13.8) 
South Asia 28.9 (13.4, 47.5) 296,000 (114,500, 518,000) 15,617,500 (13,341,000, 20,182,000) 1.9 (0.7, 3.6) 
Central Asia 40.5 (36.5, 44.5) 114,000 (69,000, 165,000) 2,516,000 (2,010,000, 2,749,000) 4.5 (2.6, 6.9) 
Caribbean 47.6 (40.2, 55.1) 37,500 (22,500, 55,000) 225,500 (183,000, 315,000) 16.7 (8.9, 30.6) 
Latin America 46.4 (43.1, 49.8) 846,000 (617,500, 1,092,500) 3,854,000 (3,131,000, 3,948,000) 22.0 (15.3, 30.4) 
North America 40.5 (29.2, 51.7) 960,000 (398,000, 1,679,500) 3,148,000 (2,429,000, 4,034,000) 30.5 (11.7, 56.7) 
Pacific Island states & terr1 41.4 (32.4, 50.5) 9,000 (5,500, 14,000) 117,500 (101,000, 376,000) 7.9 (1.9, 11.1) 
Australasia 42.8 (38.9, 46.8) 49,500 (35,500, 65,000) 278,500 (220,000, 297,000) 17.7 (12.1, 25.2) 
Sub-Saharan Africa 16.3 (12.7, 20.1) 225,000 (45,500, 458,500) 9,83,500 (7,605,000, 15,112,000) 2.3 (0.5, 5.9) 
Middle East & North Africa 36.1 (29.2, 43.2) 126,000 (65,000, 199,500) 8,625,500 (6,838,000, 9,155,000) 1.5 (0.7, 2.4) 
Global 39.2 (31.6, 47.0) 6,063,500 (3,434,500, 9,246,000) 71,146,000 (62,472,000, 79,404,000) 8.5 (4.6, 13.1) 
Notes: 
PWID – people who inject drugs; HCV - Hepatitis C virus; UI - uncertainty interval (see methods for details of estimation). 
Number of people with recent injecting drug use with viraemic HCV infection are rounded to the nearest 500. 
Total population number with viraemic HCV infection are rounded to the nearest 1,000. 
1. Note that no estimates of the prevalence of anti-HCV among people who inject drugs have been located for the Pacific Islands 
and Territories, so the weighted observed global preval nce was used here. Considerable caution should be used with these 
estimates. 
  
Page 25 of 36 Addiction
For Review Only
 
25 
 
Table 3: Country-level estimates of the prevalence of HCV viraemic infection among 
people with recent injecting drug use, the number of people with recent injecting drug 
use living with HCV viraemic infection, the total population living with HCV vireamic 
infection and the proportion of people with recent injecting drug use among the total 
population with HCV viraemic infection 
Region and country 
Prevalence of 
HCV viraemic 
infection among 
people with 
recent injecting 
drug use 
% (UI) 
Number of people with recent 
injecting drug use living with HCV 
viraemic infection 
(UI) 
Total population living with HCV 
viraemic infection  
 (UI) 
Proportion of 
people with recent 
injecting drug use 
among the total 
population with 
HCV viraemic 
infection 
% (UI) 
Eastern Europe     
Armenia                             32.0 (22.0,42.3) 4,000 (1,500, 8,500) NK NG 
Azerbaijan                          46.6 (34.9,58.0) 20,000 (14,000, 27,000) 190,000 (125,000, 212,000) 10.6 (7.3,17.3) 
Belarus                             43.7 (32.3,55.1) 18,000 (7,000, 31,500) NK NG 
Bosnia & Herzegovina               30.0 (20.7,39.5) NK NK NK 
Bulgaria                            51.5 (47.3,55.8) 9,500 (7,500, 11,500) 87,000 (46,000, 112,000) 11.0 (6.9,20.4) 
Czech Republic                     13.7 (10.9,16.7) 6,500 (5,000, 8,000) 43,000 (22,000, 48,500) 15.0 (9.2,28.6) 
Estonia                             59.4 (49.8,68.4) 5,000 (2,500, 8,500) 18,000 (11,500, 20,000) 28.2 (12.6,53.0) 
Georgia 51.8 (42.9,60.5) 59,500 (12,500, 119,500) 165,000 (120,000, 169,000) 36.1 (7.4,76.9) 
Hungary                             35.0 (22.9,47.2) 1,500 (500, 2,500) 52,500 (28,500, 55,500) 2.7 (1.1,5.6) 
Latvia                              55.8 (49.8,61.7) 8,000 (6,000, 10,000) 43,000 (28,000, 50,000) 18.1 (11.8,29.1) 
Lithuania                           30.8 (28.1,33.7) 1,500 (500, 2,500) 32,500 (20,000, 38,500) 4.5 (2.0,8.6) 
Moldova                             37.5 (25.5,49.7) 4,500 (2,500, 7,000) NK NG 
Poland                           44.0 (40.5,47.6) NK 184,000 (136,000, 224,000) NK 
Romania                             62.9 (58.7,67.0) 51,000 (36,000, 67,500) 547,000 (397,000, 566,000) 9.3 (6.0,14.2) 
Russian Federation                      51.6 (44.2,58.9) 969,500 (463,000, 1,570,500) 4,748,000 (3,238,000, 4,960,000) 20.4 (9.6,37.2) 
Slovakia                            42.1 (26.6,57.7) 8,500 (3,500, 14,500) 33,000 (20,000, 37,500) 25.4 (9.6,52.0) 
Ukraine 40.4 (36.3,44.6) 129,000 (54,000, 222,000) NK NG 
Western Europe     
Albania 25.5 (20.1,31.1) 1,500 (1,000, 2,500) NK NG 
Andorra NK NK NK NK 
Austria 45.7 (40.6,50.9) 8,500 (6,000, 11,500) 21,000 (6,000, 30,500) 40.2 (20.1,100.0) 
Belgium 43.8 (34.9,52.6) 11,500 (7,000, 16,500) 64,500 (23,000, 75,500) 17.8 (8.7,45.8) 
Croatia                             27.5 (21.0,34.2) 1,500 (1,000, 2,500) 26,000 (16,500, 28,500) 6.7 (4.0,11.3) 
Denmark 31.9 (26.8,37.2) 5,500 (4,000, 6,500) 19,500 (14,500, 19,500) 27.2 (18.8,39.5) 
England 23.1 (20.0,26.3) 48,500 (41,500, 56,000) 168,000 (91,000, 211,000) 28.9 (18.8, 51.8) 
Finland 55.2 (51.2,59.4) 9,500 (7,000, 12,500) 22,500 (16,000, 26,000) 41.6 (27.4,62.8) 
France  48.0 (44.5,51.5) 39,500 (31,500, 47,500) 194,000 (92,500, 222,000) 20.2 (12.4,40.1) 
FYR (Form. Yug. Rep) 
Macedonia 46.6 (43.4,49.9) 2,500 (1,500, 3,000) 
NK 
NK 
Germany 48.7 (44.6,53.0) 64,000 (13,500, 129,000) 205,000 (90,000, 313,000) 31.3 (6.2,80.6) 
Greece 49.2 (45.4,53.1) 2,500 (2,000, 3,000) 132,000 (82,000, 169,000) 1.9 (1.2,3.1) 
Greenland -- -- NK -- 
Iceland 47.3 (43.8,50.8) NK 1,000 (1,000, 1,000) NK 
Ireland 56.0 (52.5,59.4) 5,000 (3,500, 6,000) 29,500 (20,000, 42,500) 16.2 (10.0,28.9) 
Italy 43.4 (38.8,48.1) 148,500 (98,500, 205,000) 680,000 (455,000, 1,641,000) 21.8 (7.6,33.9) 
Liechtenstein -- -- NK -- 
Luxembourg 61.0 (55.9,66.1) 1,500 (1,000, 1,500) 5,500 (3,500, 6,000) 25.2 (16.6,41.1) 
Malta 18.9 (10.4,28.4) NK 1,000 (1,000, 1,500) NK 
Monaco NK NK NK NK 
Montenegro 32.6 (29.4,35.9) NK NK NK 
Netherlands 41.5 (36.7,46.3) 1,500 (1,000, 2,000) 16,500 (5,000, 25,500) 8.3 (4.2,22.9) 
Northern Ireland NK NK NK NK 
Norway 48.6 (44.5,52.8) 4,000 (3,500, 5,000) 21,000 (15,000, 24,500) 19.4 (13.8,28.1) 
Portugal 65.8 (59.1,72.2) 10,500 (9,000, 12,000) 89,000 (74,000, 120,000) 11.7 (8.2,18.1) 
San Marino NK NK NK NK 
Scotland 39.1 (33.8,44.5) 6,000 (5,000, 7,500) NK NG 
Serbia 19.4 (16.5,22.6) 5,500 (4,500, 7,000) NK NG 
Slovenia 22.9 (19.6,26.2) 1,500 (1,000, 2,000) 6,500 (4,500, 7,000) 21.3 (13.3,33.5) 
Spain 53.3 (50.2,56.3) 5,500 (2,000, 9,500) 386,000 (202,000, 620,000) 1.4 (0.5,3.6) 
Sweden 61.3 (57.6,64.9) 5,000 (<500, 20,000) 37,500 (28,000, 43,500) 13.3 (0.0,46.6) 
Switzerland 55.9 (51.0,60.9) 7,500 (6,000, 9,500) 78,000 (45,500, 87,000) 9.7 (6.3,16.7) 
Wales 20.1 (17.2,23.0) NK NK NK 
East and South East 
Asia 
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Region and country 
Prevalence of 
HCV viraemic 
infection among 
people with 
recent injecting 
drug use 
% (UI) 
Number of people with recent 
injecting drug use living with HCV 
viraemic infection 
(UI) 
Total population living with HCV 
viraemic infection  
 (UI) 
Proportion of 
people with recent 
injecting drug use 
among the total 
population with 
HCV viraemic 
infection 
% (UI) 
Brunei Darussalam                  NK NK NK NK 
Cambodia                            NK NK 257,000 (147,000, 272,000) NK 
China                               32.3 (20.8,44.3) 828,000 (493,000, 1,228,500) 9,795,000 (6,675,000, 10,832,000) 8.5 (4.6,14.3) 
Indonesia 66.9 (62.2,71.5) 127,500 (103,000, 153,000) 1,289,000 (443,000, 2,046,000) 9.9 (5.5,24.9) 
Japan                               48.6 (40.8,56.3) 179,000 (130,500, 234,500) 857,000 (364,000, 1,024,000) 20.9 (11.7,46.5) 
Lao PDR                             NK NK NK NK 
Malaysia                            50.3 (46.2,54.5) 142,000 (116,000, 169,500) 382,000 (240,000, 405,000) 37.1 (25.2,59.2) 
Mongolia                            NK NK 194,000 (131,000, 237,000) NK 
Myanmar                             22.2 (19.9,24.5) 38,500 (25,500, 53,000) NK NG 
North Korea                          -- -- NK -- 
Philippines                         26.4 (12.8,41.6) 6,500 (3,000, 11,500) 614,000 (353,000, 651,000) 1.1 (0.4,2.3) 
Republic of Korea                  36.3 (31.7,41.0) NK 231,000 (148,000, 261,000) NK 
Singapore                           31.9 (28.9,35.0) NK NK NK 
Taiwan 68.2 (64.4,72.0) NK 489,000 (310,000, 877,000) NK 
Thailand                            66.4 (60.6,71.9) 34,000 (12,500, 60,000) 463,000 (255,000, 487,000) 7.4 (2.6,16.1) 
Timor Leste                         NK NK NK NK 
Viet Nam                            43.8 (31.8,55.7) 70,500 (47,000, 98,000) 1,066,000 (580,000, 1,116,000) 6.6 (3.7,12.5) 
South Asia     
Afghanistan 28.4 (20.7,36.3) 39,500 (23,000, 60,000) 183,000 (85,000, 258,000) 21.5 (10.5,46.9) 
Bangladesh 25.4 (16.9,34.4) 17,500 (11,500, 24,000) NK NG 
Bhutan NK NK NK NK 
India 30.0 (25.2,34.9) 59,000 (38,000, 84,000) 6,245,000 (4,748,000, 10,957,000) 0.9 (0.4,3.0) 
Iran 33.1 (21.4,45.2) 52,000 (29,500, 81,000) 199,000 (129,000, 226,000) 26.2 (13.2,47.0) 
Maldives 0.5 (0.0,1.4) <500 (<500,<500) NK NG 
Nepal 33.4 (23.1,43.8) 12,000 (8,000, 15,500) NK NG 
Pakistan 27.4 (0.0,60.6) 116,000 (<500, 173,500) 7,172,000 (5,363,000, 7,487,000) 1.6 (0.7,3.6) 
Sri Lanka NK NK NK NK 
Central Asia     
Kazakhstan                          44.1 (39.8,48.4) 49,500 (30,000, 71,500) 508,000 (334,000, 572,000) 9.8 (5.4,16.7) 
Kyrgyzstan                          32.9 (29.9,36.0) 9,500 (5,500, 13,500) NK NG 
Tajikistan 46.0 (41.9,50.2) 11,000 (6,500, 15,500) NK NG 
Turkmenistan                      NK NK NK NK 
Uzbekistan 38.8 (34.7,43.0) 36,500 (22,500, 53,000) 1,292,000 (902,000, 1,524,000) 2.8 (1.6,4.6) 
Caribbean     
Antigua & Barbuda -- -- NK -- 
Bahamas                             NK NK NK NK 
Barbados -- -- NK -- 
Bermuda                               NK NK NK NK 
Comm. of Puerto Rico 58.8 (53.9,63.7) 16,500 (10,000, 24,000) 35,500 (23,000, 60,500) 46.6 (22.1,100.0) 
Cuba                                -- -- 35,000 (13,500, 77,000) -- 
Dominica                            -- -- NK -- 
Dominican Republic                 NK NK 68,000 (41,500, 108,000) NK 
Grenada                             -- -- NK -- 
Haiti                               NK NK NK NK 
Jamaica                             NK NK NK NK 
Saint Kitts & Nevis -- -- NK -- 
Saint Lucia -- -- NK -- 
St Vincent & the 
Grenadines -- -- 
NK 
-- 
Trinidad & Tobago -- -- NK -- 
Latin America     
Argentina 41.0 (37.5,44.4) 33,000 (30,000, 36,000) 326,000 (144,000, 490,000) 10.1 (6.3,21.0) 
Belize -- -- NK -- 
Bolivia NK NK NK NK 
Brazil 47.9 (44.3,51.5) 461,000 (336,500, 596,500) 1,787,000 (1,293,000, 1,896,000) 25.8 (17.2,38.5) 
Chile NK NK 56,500 (31,000, 94,000) NK 
Colombia 21.6 (19.3,24.0) NK 409,000 (272,000, 436,000) NK 
Costa Rica NK NK NK NK 
Ecuador NK NK NK NK 
El Salvador NK NK NK NK 
Guatemala NK NK NK NK 
Guyana NK NK NK NK 
Honduras NK NK NK NK 
Mexico 71.5 (67.3,75.5) 107,500 (70,500, 149,000) 532,000 (304,000, 557,000) 20.2 (11.4,37.2) 
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Region and country 
Prevalence of 
HCV viraemic 
infection among 
people with 
recent injecting 
drug use 
% (UI) 
Number of people with recent 
injecting drug use living with HCV 
viraemic infection 
(UI) 
Total population living with HCV 
viraemic infection  
 (UI) 
Proportion of 
people with recent 
injecting drug use 
among the total 
population with 
HCV viraemic 
infection 
% (UI) 
Nicaragua NK NK NK NK 
Panama NK NK 12,500 (7,500, 13,500) NK 
Paraguay 7.4 (5.8,9.0) NK NK NK 
Peru NK NK 167,000 (99,000, 182,000) NK 
Suriname NK NK NK NK 
Uruguay 16.4 (14.1,18.9) 1,000 (<500, 2,500) NK NG 
Venezuela NK NK 118,000 (58,500, 126,000) NK 
North America     
Canada 52.9 (44.5,61.2) 65,000 (50,000, 82,000) 212,000 (136,000, 246,000) 30.7 (20.2,49.3) 
United States 39.8 (28.4,51.3) 895,000 (353,500, 1,601,500) 2,936,000 (2,231,000, 3,826,000) 30.5 (10.9,58.9) 
Pacific Island States & 
Terr. 
 
   
American Samoa NK NK NK NK 
Fed. States of Micronesia NK NK NK NK 
Fiji NK NK 500 (<500, 3,000) NK 
French Polynesia NK NK NK NK 
Guam NK NK NK NK 
Kiribati NK NK NK NK 
Marshall Islands NK NK NK NK 
Nauru -- -- NK -- 
New Caledonia NK NK NK NK 
Northern Mariana Islands NK NK NK NK 
Palau NK NK NK NK 
Papua New Guinea NK NK 94,500 (70,500, 328,000) NK 
Samoa NK NK <500 (<500, <500) NK 
Solomon Islands NK NK NK NK 
Tonga NK NK NK NK 
Tuvalu -- -- NK -- 
Vanuatu NK NK NK NK 
Australasia     
Australia                           40.1 (36.9,43.5) 37,500 (27,500, 48,500) 230,000 (178,000, 244,000) 16.2 (11.1,23.2) 
New Zealand                        53.9 (46.8,61.1) 12,000 (8,000, 16,500) 48,500 (30,000, 62,500) 25.0 (14.7,42.9) 
Sub Saharan Africa     
Angola NK NK NK NK 
Benin NK NK NK NK 
Botswana -- -- NK -- 
Burkina Faso NK NK 247,000 (189,000, 256,000) NK 
Burundi NK NK 120,000 (93,000, 459,000) NK 
Cameroon NK NK 164,000 (117,000, 184,000) NK 
Cape Verde NK NK NK NK 
Central African Republic -- -- 15,500 (11,000, 17,500) -- 
Chad NK NK 162,000 (111,000, 184,000) NK 
Comoros -- -- NK -- 
Congo (Kinshasa) NK NK NK NK 
Cote d'Ivoire 1.3 (0.0,7.1) <500 (<500, <500) NK NG 
Djibouti NK NK NK NK 
Equatorial Guinea -- -- NK -- 
Eritrea -- -- NK -- 
Ethiopia NK NK 647,000 (410,000, 726,000) NK 
Gabon NK NK 124,000 (90,000, 129,000) NK 
Gambia NK NK 17,000 (10,000, 27,000) NK 
Ghana 30.1 (25.8,34.4) NK 399,000 (305,000, 944,000) NK 
Guinea NK NK NK NK 
Guinea-Bissau -- -- NK -- 
Kenya 12.3 (7.4,17.7) 4,000 (1,000, 7,500) 115,000 (42,500, 126,000) 3.3 (0.7,5.2) 
Lesotho -- -- NK -- 
Liberia NK NK NK NK 
Madagascar 4.2 (1.8,7.0) 500 (<500, 3,000) 56,000 (39,000, 81,000) 1.2 (0.0,5.1) 
Malawi NK NK NK NK 
Mali NK NK NK NK 
Mauritania -- -- NK -- 
Mauritius 72.8 (68.8,76.7) 5,000 (1,500, 9,500) NK NG 
Mozambique 50.3 (46.2,54.4) 14,500 (<500, 31,000) NK NG 
Namibia -- -- NK -- 
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Region and country 
Prevalence of 
HCV viraemic 
infection among 
people with 
recent injecting 
drug use 
% (UI) 
Number of people with recent 
injecting drug use living with HCV 
viraemic infection 
(UI) 
Total population living with HCV 
viraemic infection  
 (UI) 
Proportion of 
people with recent 
injecting drug use 
among the total 
population with 
HCV viraemic 
infection 
% (UI) 
Niger NK NK NK NK 
Nigeria 4.3 (2.1,6.8) NK 2,553,000 (1,902,000, 2,651,000) NK 
Rep. of the Congo -- -- NK -- 
Rwanda NK NK NK NK 
Sao Tome & Principe -- -- NK -- 
Senegal 29.5 (22.9,36.3) NK NK NK 
Seychelles 31.5 (27.2,36.0) 500 (500, 500) NK NG 
Sierra Leone NK NK NK NK 
Somalia NK NK NK NK 
South Africa NK NK 356,000 (227,000, 441,000) NK 
Swaziland NK NK NK NK 
Togo NK NK NK NK 
Uganda NK NK NK NK 
United Rep.  of Tanzania 20.8 (16.4,25.4) 71,500 (41,000, 108,000) NK NG 
Zambia NK NK NK NK 
Zimbabwe NK NK NK NK 
Middle East & North 
Africa 
 
   
Algeria NK NK 388,000 (140,000, 674,000) NK 
Bahrain NK NK 17,000 (11,000, 17,500) NK 
Cyprus 37.3 (32.9,41.8) <500 (<500, <500) NK NG 
Egypt 37.1 (26.7,47.5) NK 5,625,000 (4,007,000, 6,044,000) NK 
Iraq NK NK 85,500 (60,500, 96,500) NK 
Israel 34.0 (28.3,39.9) NK 100,000 (60,000, 103,000) NK 
Jordan NK NK 24,500 (10,500, 29,000) NK 
Kuwait NK NK NK NK 
Lebanon 17.6 (10.5,25.2) NK 7,500 (3,000, 18,000) NK 
Libyan Arab Jamahiriya 70.9 (66.4,75.2) 1,500 (500, 2,000) 41,500 (32,000, 43,000) 3.3 (1.7,5.5) 
Morocco 40.4 (25.4,55.8) 12,500 (5,500, 21,000) 263,000 (190,000, 328,000) 4.7 (1.9,8.5) 
Occ. Palestinian Terr. 31.2 (26.3,36.2) NK NK NK 
Oman NK NK 15,500 (12,000, 17,500) NK 
Qatar NK NK 37,500 (29,500, 40,000) NK 
Saudi Arabia 58.3 (53.7,63.0) NK 106,000 (78,500, 190,000) NK 
South Sudan -- -- NK -- 
Sudan NK NK NK NK 
Syrian Arab Rep. 2.5 (0.9,4.3) NK 554,000 (245,000, 653,000) NK 
Tunisia 21.8 (19.0,24.7) NK 108,000 (25,000, 123,000) NK 
Turkey 33.7 (30.7,36.7) NK 492,000 (271,000, 763,000) NK 
United Arab Emirates NK NK 131,000 (50,000, 159,000) NK 
Yemen NK NK 211,000 (143,000, 258,000) NK 
Notes: 
-- Indicates no evidence located that injecting drug use was occurring in this country. 
NK Indicates no estimate of prevalence of that HCV was located, yet evidence of injecting drug use occurring in that country was 
identified. 
NR indicates that uncertainty was not estimated around the estimate. 
NG Indicates that no estimate of HCV amongst the general population was available. 
Italic font indicates that those uncertainty intervals were estimated in this review. 
PWID – people who inject drugs; HCV – Hepatitis C virus; UI - uncertainty interval (see methods for details of estimation). 
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Figure 1: Estimated prevalence of HCV viraemic infection among people with recent injecting drug use, 
by country 
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Figure 2: Estimated number of people with recent injecting drug use living with HCV viraemic infection, 
by country  
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Figure 3: Countries with the greatest total number of people with HCV viraemic infection among people 
with recent injecting drug use globally. The size of the bubble represents the total proportion of hepatitis C 
viraemic infections that among people with recent injecting drug use. An X indicates that data were not 
available to calculate the total proportion of viraemic HCV infections among people with recent injecting drug 
use.  
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Figure 4: Estimated proportion of people with recent injecting drug use among the total population with 
HCV viraemic infection, by country  
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